A Global Market Overview" report has been added to ResearchAndMarkets.com's offering.The global Intraocular Lens (IOL) market ...

Good news is, Medicare does cover necessary cataract surgery including the removal of the cataract and the addition of a ...

Bausch + Lomb said enVista Envy intraocular lenses will be commercially available in the U.S. on a limited basis in the coming weeks and more broadly in 2025. The company is in the process of seeking ...

Johnson & Johnson (NYSE: JNJ) expanded the rollout of its latest Tecnis Odyssey presbyopia-correcting intraocular lenses ...

enVista Envy IOLs will be commercially available in the U.S. on a limited basis in the coming weeks and more broadly in 2025. Bausch + Lomb is also in the process of seeking regulatory approvals for ...

The FineVision trifocal diffractive IOL has three focal ... the implant of a fully-diffractive lens, while scores for refractive and refractive-diffractive multifocal IOLs tended to improve ...

Recent advances have led to intraocular lenses that offer multifocality – the opportunity to have near as well as distance vision, without glasses. Some multifocal lenses are even in the ...

Cooper’s pricing power and cost optimization efforts are expected to drive margin expansion. Read why I reiterate a Buy ...

The intraocular lens (IOL) market growth is driven by various ... Advancements in technology, like multifocal and toric lenses, enhance visual results further boosting the market demand.

Bausch + Lomb Corp. (BLCO, BLCO.TO) announced that the U.S. Food and Drug Administration has approved the enVista Envy full range of ...

Shares in Bausch + Lomb were higher after the company received approval from the Food and Drug Administration for its enVista Envy full range of vision intraocular lens. Shares were recently up 23% at ...